1. Home
  2. AYTU vs GMM Comparison

AYTU vs GMM Comparison

Compare AYTU & GMM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • AYTU
  • GMM
  • Stock Information
  • Founded
  • AYTU N/A
  • GMM 2017
  • Country
  • AYTU United States
  • GMM China
  • Employees
  • AYTU N/A
  • GMM N/A
  • Industry
  • AYTU Biotechnology: Pharmaceutical Preparations
  • GMM
  • Sector
  • AYTU Health Care
  • GMM
  • Exchange
  • AYTU Nasdaq
  • GMM Nasdaq
  • Market Cap
  • AYTU 10.5M
  • GMM 9.8M
  • IPO Year
  • AYTU N/A
  • GMM 2023
  • Fundamental
  • Price
  • AYTU $1.72
  • GMM $3.51
  • Analyst Decision
  • AYTU
  • GMM
  • Analyst Count
  • AYTU 0
  • GMM 0
  • Target Price
  • AYTU N/A
  • GMM N/A
  • AVG Volume (30 Days)
  • AYTU 27.9K
  • GMM 135.7K
  • Earning Date
  • AYTU 02-12-2025
  • GMM 02-03-2025
  • Dividend Yield
  • AYTU N/A
  • GMM N/A
  • EPS Growth
  • AYTU N/A
  • GMM 62.17
  • EPS
  • AYTU N/A
  • GMM 6.37
  • Revenue
  • AYTU $79,759,000.00
  • GMM $41,360,953.00
  • Revenue This Year
  • AYTU N/A
  • GMM N/A
  • Revenue Next Year
  • AYTU N/A
  • GMM N/A
  • P/E Ratio
  • AYTU N/A
  • GMM $0.61
  • Revenue Growth
  • AYTU N/A
  • GMM 53.82
  • 52 Week Low
  • AYTU $1.30
  • GMM $0.21
  • 52 Week High
  • AYTU $3.45
  • GMM $4.97
  • Technical
  • Relative Strength Index (RSI)
  • AYTU 54.22
  • GMM 48.77
  • Support Level
  • AYTU $1.68
  • GMM $3.55
  • Resistance Level
  • AYTU $1.93
  • GMM $4.16
  • Average True Range (ATR)
  • AYTU 0.12
  • GMM 0.57
  • MACD
  • AYTU 0.00
  • GMM -0.11
  • Stochastic Oscillator
  • AYTU 36.36
  • GMM 4.56

About AYTU Aytu BioPharma Inc.

Aytu BioPharma Inc is a specialty pharmaceutical company with a commercial portfolio of prescription therapeutics and consumer health products. The company's primary prescription products treat attention deficit hyperactivity disorder and other common pediatric conditions. It is building a complementary therapeutic development pipeline including a prospective treatment (AR101/enzastaurin) for vascular Ehlers-Danlos Syndrome, a rare genetic disease resulting in high morbidity and a significantly shortened lifespan. The company operates in two segments Rx Segment, consisting of prescription pharmaceutical products and Consumer Health segments of which the company generates maximum revenue from the Rx segment.

About GMM Global Mofy Metaverse Limited

Global Mofy AI Ltd, formerly Global Mofy Metaverse Ltd operates as a technology solutions provider engaged in virtual content production, digital marketing, and digital assets development for the metaverse industry. It utilizes its proprietary Mofy Lab technology platform which consists of three-dimensional (3D) rebuilt technology and artificial intelligence (AI) interactive technology to create a 3D high-definition virtual version of a wide range of physical world objects such as human, animal, and scenes which can be used in different applications.

Share on Social Networks: